To further confirm the selectivity of the inhibitory effect of solasonine on Hh pathway activity, we tested its effect on a panel of kinases activity, especially the receptor tyrosine kinases that have been the most frequently used targets to develop molecular targeted anti-cancer drugs, such as vascular growth factor receptor 1 (VEGFR1), VEGFR2, c-kit, RET, three members of epidermal growth factors (EGFR) family, ephrin type-A receptor 2 (EPH-A2), insulin-like growth factor 1 receptor (IGF1R), fibroblast growth factor receptor (FGFR1). This evidence concerns the gene KIT and cancer.